rhapsido – Lab DB

Pharmaceutical R&D

Novartis Secures Dual Regulatory Milestones: European Approval for Rhapsido and WHO Prequalification for Coartem Baby

Teuku Ryan Apr 27, 2026 0

Novartis has achieved significant regulatory successes on two fronts, with its oral therapy Rhapsido (remibrutinib) receiving marketing authorisation from the…

Novartis Secures Dual Regulatory Milestones: European Approval for Rhapsido and WHO Prequalification for Coartem Baby

YOU MAY HAVE MISSED

The Genetic Legacy of Paternal Aging: How Intra-Testicular Selection Drives Disease-Causing Mutations in Sperm

Pens to pills: what oral GLP-1s change at the bench

Arc Protein Identified as Key Driver in the Spread of Toxic Tau Proteins in Alzheimer’s Disease

Talawar Therapeutics and JATT II Acquisition Complete Business Combination to Advance Novel Immunology Therapeutics